KRAS and non-small cell lung carcinoma: Overall, approximately 50–70% Asian and 30–40% non-Asian patients with metastatic non-squamous NSCLC carry druggable mutations (epidermal growth factor receptor EGFR, anaplastic lymphoma kinase ALK, ROS proto-oncogene 1 ROS1, rearranged during transfection RET, B-Raf proto-oncogene BRAF, MET proto-oncogene MET, Kirsten rat sarcoma virus KRAS, Neurotrophic tyrosine receptor kinase NTRK), and the use of the appropriate targeted drugs results in a manifold increase in their overall survival [21,26].